ArticleNaunyn-Schmiedeberg's archives of pharmacology2020

NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway.

Durgesh Kumar Dwivedi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.